Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies

Study summary

To estimate the maximum tolerated dose (MTD) or recommended dose for phase II (RP2D) of CLR457 and to investigate the anti-tumor activity of CLR457

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedCLR457

The study team can explain what participation involves.

Who it may be forAdvanced Solid Tumor

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Dec 3, 2021 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?7 U.S. locations

Locations may change over time.

Who runs it?Novartis Pharmaceuticals

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1
Sponsor: Novartis Pharmaceuticals
Interventions being studied: Drug: CLR457

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Written informed consent must be obtained prior to any screening procedures
Phase I: Patients with advanced/metastatic solid tumors, with measurable or non-measurable disease as determined by modified RECIST version 1.1 who have progressed despite standard therapy or be intolerant of standard therapy, or for whom no standard therapy exists, who have tumors harboring one of the following: confirmed PIK3CA mutation or amplification, PTEN loss of function, EGFR mutation, cMET activation and/or HER2 overexpression. Endometrial carcinoma will not be selected for any molecular status.
Phase II: Patients with advanced/metastatic solid tumors, with at least one measurable lesion as determined by modified RECIST version 1.1, who progressed despite standard therapy or be intolerant of standard therapy, or for whom no standard therapy exists, fitting in one of the following groups: Group 1: patients with PIK3CA mutated or amplified ER positive (ER+) breast cancer ; Group 2: patients with endometrial carcinoma (not selected for any molecular status); Group 3: patients with solid tumors (with the exception of PIK3CA mutant/amplified ER+ breast cancer and endometrial carcinoma) harboring PIK3CA mutation or amplification/any PTEN status; Group 4: patients with solid tumors (with the exception of endometrial carcinoma) harboring PTEN loss of function/ PIK3CA wild type; Group 5: non-small cell lung cancer harboring cMET activation and/or EGFR mutation. Up to 3 lines of chemotherapy allowed in advanced/metastatic setting.
ECOG Performance Status ≤ 2.
Availability of a representative formalin fixed paraffin embedded tumor tissue sample. If archival tumor sample is not available, a newly obtained tumor sample needs to be submitted instead.

Reasons someone may not be able to joinExclusion criteria

Brain metastasis unless treated and neurologically stable
Patient having out of range laboratory values defined as: Hepatic and renal function:
Serum total Bilirubin ≥ 1.5 x ULN (upper limit of normal) or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 2.5 x ULN
For patients with tumor involvement of the liver AST or ALT \> 5 x ULN
For patients with Gilbert's syndrome total bilirubin \> 2.5 x ULN
Serum creatinine \> 1.5 x ULN and/or measured or calculated creatinine clearance \< 75% LLN (lower limit of normal) Bone marrow function:
Platelets \< 100 x 109/L
Hemoglobin (Hgb) \< 9 g/dL
Absolute Neutrophil Count (ANC) \< 1.5 x 109/L Cardiac function:
Clinically significant and/or uncontrolled heart disease such as congestive heart failure (CHF) requiring treatment (NYH grade ≥2), hypertension or arrhythmia
Left ventricular ejection fraction (LVEF) \< 45% as determined by MUGA scan or ECHO
QTcF \>480 msec on screening ECG or congenital long QT syndrome
Acute myocardial infarction (AMI) or unstable angina pectoris \< 3 months prior to study entry
Peripheral neuropathy CTCAE Grade ≥2
History of pancreatitis of any grade
Patients with diabetes mellitus requiring insulin treatment and/or with clinical signs or with Fasting Plasma Glucose (FPG) ≥ 140 mg/dL / 7.8 mmol/L
Patients receiving treatment with medications that are known to be 1) strong inhibitors or inducers of CYP3A4/5; 2) CYP2C9 substrate with narrow therapeutic index; 3) QT prolonging agents; 4) proton pump inhibitors unless these medications can be discontinued at least a week prior to start of treatment. Other protocol-defined inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Massachusetts General Hospital SC-9Boston, Massachusetts
Memorial Sloan Kettering SC-4New York, New York
Tennessee Oncology SCNashville, Tennessee
Novartis Investigative SiteToronto, Ontario
Novartis Investigative SiteKashiwa, Chiba
Novartis Investigative SiteSingapore
Novartis Investigative SiteBarcelona, Catalonia

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 3, 2021. Always confirm current availability with the study team.

View original record ↗